Blood-Brain Barrier in vitro Model: A Tissue Engineering Approach and Validation

Zhang, Zhiqi

doi:10.25148/etd.fi10081003

Cited by 3 publications

(1 citation statement)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, BMECs possess few pinocytotic vesicles, and its mitochondrial content (both quantity and volume) is also high, which limit the transcytosis and fuel the increased demand of transport activity associated with the endothelial influx–efflux pump, respectively . Only selected molecules necessary for ideal functional efficiency of the brain such as certain amino acids, monocarboxylic acids, amines, sugars, purine bases, and hydrophilic molecules such as O 2 and CO 2 are actively transported via mechanisms such as carrier mediated transport, fluid‐phase endocytosis, and receptors‐mediated or absorptive‐mediated endocytosis . Many substrate‐specific transporters such as monocarboxylate transport system, glucose transporter‐1, insulin receptor, transferrin receptor, and ceruloplasmin receptor are present on the BMECs .…”

Section: Problems Of Neuroaids Treatmentsmentioning

confidence: 99%

Towards nanomedicines for neuroAIDS

Sagar

Pilakka-Kanthikeel

Pottathil

et al. 2014

Reviews in Medical Virology

View full text Add to dashboard Cite

Although Highly Active Antiretroviral Therapy (HAART) has resulted in remarkable decline in the morbidity and mortality in AIDS Patients, controlling HIV infections still remain a global health priority. HIV access to the central nervous system (CNS) serves as the natural viral preserve because most anti-retro viral (ARV) drugs possess inadequate or zero delivery across the brain barriers. Thus, development of target-specific, effective, safe and controllable drug-delivery approach is an important health priority for global elimination of AIDS progression. Emergence of nanotechnology in medicine has shown exciting prospect for development of novel drug delivery systems to administer the desired therapeutic levels of ARV drugs in the CNS. Neuron-resuscitating and/or anti-dependence agents may also be delivered in the brain though nanocarriers to countercheck the rate of neuronal degradation during HIV infection. Several nanovehicles such as liposomes, dendrimers, polymeric nanoparticles, micelles, solid lipid nanoparticles, etc. have been intensively explored. Recently, magnetic nanoparticles and monocytes/macrophages have also been used as carrier to improve the delivery of nanoformulated ARV drugs across the blood-brain barrier (BBB). Nevertheless, more rigorous research-homework has to be elucidated to sort out the shortcomings that affect the target specificity, delivery, release and/or bioavailability of desired amount of drugs for treatment of neuroAIDS.

show abstract

Section: Problems Of Neuroaids Treatmentsmentioning

confidence: 99%